Received Feb 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
Following vaccination, the plaques thickened and new tumors developed/Clinical evidence of disease progression characterized by the multiple cutaneous tumors; Following vaccination, the plaques thickened and new tumors developed/Clinical evidence of disease progression characterized by the multiple cutaneous tumors; This is a literature report for the following literature source(s): "Mycosis Fungoides Progression Following COVID-19 mRNA Vaccination. A 53-year-old male patient received COVID-19 Vaccine - Manufacturer Unknown, in 2021 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "stage IB MF (T2N0M0B0)", start date: 2014 (unspecified if ongoing), notes: ~; "stem cell transplant", start date: Feb2015 (unspecified if ongoing); "PUVA" (unspecified if ongoing), notes: used to manage recurrence of patches and plaques without tumors; "Steroids" (unspecified if ongoing), notes: topical, used to manage recurrence of patches and plaques without tumors. The patient's concomitant medications were not reported. Past drug history included: Nitrogen mustard for recurrence stage IB MF (T2N0M0B0), notes: recurrence of patches and plaques without tumors; 5-fluorouracil for recurrence stage IB MF (T2N0M0B0), notes: recurrence of patches and plaques without tumors; Bexarotene for recurrence stage IB MF (T2N0M0B0), notes: recurrence of patches and plaques without tumors; Brentuximab for recurrence stage IB MF (T2N0M0B0), notes: recurrence of patches and plaques without tumors; Interferon-alpha (inf-alpha) for recurrence stage IB MF (T2N0M0B0), notes: recurrence of patches and plaques without tumors. The following information was reported: CUTANEOUS T-CELL LYMPHOMA STAGE I (death, medically significant, life threatening), MALIGNANT NEOPLASM PROGRESSION (death, medically significant, life threatening) all with onset Apr2021, outcome "fatal" and all described as "Following vaccination, the plaques thickened and new tumors developed/Clinical evidence of disease progression characterized by the multiple cutaneous tumors". The patient underwent the following laboratory tests and procedures: Biopsy: confirmed CTCL with stable disease/partial, notes: remission before vaccination who then deteriorated (new tumors, large-cell transformation, systemic spread, or death); Imaging procedure: developed widely scattered tumors, notes: and nodal/pleural involvement; Physical examination: Clinical presentation of recurrent patches and, notes: plaques without evidence of tumors follow stem cell transplant. Therapeutic measures were taken as a result of cutaneous t-cell lymphoma stage i, malignant neoplasm progression. The patient date of death was 17Aug2023. Reported cause of death: "Following vaccination, the plaques thickened and new tumors developed/Clinical evidence of disease progression characterized by the multiple cutaneous tumors". It was not reported if an autopsy was performed. Clinical course: The patient with MF diagnosed in 2014 (T2N0M0B0). After progression to tumors with large cell transformation, he received a stem cell transplant in Feb2015. One year post transplant, he had recurrence of patches and plaques without tumors, managed with topical steroids, nitrogen mustard (TNM), PUVA, 5-fluorouracil, bexarotene, brentuximab, and interferon alpha (IFN-alpha). By early 2021 he had patch and plaque disease without tumors that had remained stable for years. Stable Plaque disease without tumors x6 yrs post-SCT in 2015; stable on multiple therapies. The duration of disease pre-vaccination was of 7 years. Following vaccination in Feb-Mar 2021, the plaques thickened and new tumors developed by April 2021. Despite multiple lines of therapy, including anti-CD30 rechallenge, clinical trial cIAP inhibitor, photopheresis, HDAC inhibitors, focal radiotherapy, and later chemotherapy, he developed widely scattered tumors and nodal/pleural involvement on imaging. He unfortunately passed away on 17Aug2023.; Sender's Comments: The reported events Cutaneous T-cell lymphoma stage I, malignant neoplasm progression are likely due to the natural course of the underlying malignancy and not related to suspect product. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate. Linked Report(s) : US-PFIZER INC-202600023230 Same article/ drug/event and different patient; US-PFIZER INC-202600023229 Same article/ drug/event and different patient; US-PFIZER INC-202600023231 Same article/ drug/event and different patient; US-PFIZER INC-202600023232 Same article/ drug/event and different patient;; Reported Cause(s) of Death: Following vaccination, the plaques thickened and new tumors developed/Clinical evidence of disease progression characterized by the multiple cutaneous tumors; Following vaccination, the plaques thickened and new tumors developed/Clinical evidence of
Medical History/Concurrent Conditions: Mycosis fungoides stage I (~); PUVA (used to manage recurrence of patches and plaques without tumors); Stem cell transplant; Steroid therapy (topical, used to manage recurrence of patches and plaques without tumors)
Test Name: biopsy; Result Unstructured Data: Test Result:confirmed CTCL with stable disease/partial; Comments: remission before vaccination who then deteriorated (new tumors, large-cell transformation, systemic spread, or death).; Test Name: Imaging; Result Unstructured Data: Test Result:developed widely scattered tumors; Comments: and nodal/pleural involvement; Test Name: Physical examination; Result Unstructured Data: Test Result:Clinical presentation of recurrent patches and; Comments: plaques without evidence of tumors follow stem cell transplant